Samsung Life Public Welfare Foundation

Pangen Biotech Inc.

Samsung Electro-mechanics Co., Ltd.

Mbd Co., Ltd.

Korea Research Institute of Chemical Technology

Aimed Bio Inc.

Do Hyun Nam

Kyeung Min Joo

Yong Uk Shin

Jae Hyun Lee

Dong Woo Lee

Bong Gu Kang

Chang-Seok Ki

Kwang Woo Kim

Bo Sung Ku

Gildon Choi

Heeyeong Cho

Dae Young Jeong

Woo Kyu Park

Jong Won Kim

Seung Chyul Hong

Don Jung Lee

Ho Jeong Song

Hyeon Young Kim

Yeon Sook Choi

YeonSook Choi

Ju Yuon Jin

Sunkyung Lee

Ho Jun Seol

Technology for a pillar structure for a biochip is disclosed. The pillar structure for a biochip includes: a substrate portion having a plate structure; an insertion pillar portion formed in one piece with the substrate portion and protruding downward from a lower surface of the substrate portion so as to be inserted into a well; and a compensation pillar portion formed in one piece with the substrate portion, the compensation pillar portion corresponding to the insertion pillar portion and protruding upward from an upper surface of the substrate portion. Therefore, when the pillar structure is cooled during an injection molding process, the substrate portion is prevented from being partially recessed, and when samples are analyzed using microscopic images, accuracy and reliability may be improved.

Pillar structure for biochip

The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.

Antibody to human and mouse SEMA3A and use thereof

Antibody to human and mouse Sema3A and use thereof

Provided is a method for producing a glioblastoma mouse model and the mouse model produced thereby, the method including the steps of: (a) dividing a glioblastoma tissue, isolated from a patient, into 4 or more sections, and collecting one or more pieces from each of the sections; (b) dissociating a mixture of the collected pieces into glioblastoma cells as single cells; and (c) orthotopically transplanting a graft sample containing the glioblastoma cells obtained in step (b), into the brain of an immunodeficient mouse. Further provided are a method of screening a glioblastoma therapeutic agent using the mouse model and a method of providing information for selection of a patient-specific glioblastoma therapy using the mouse model. The glioblastoma mouse model shows the same genetic, morphological and pathological characteristics as those of the parental tumor, and it allows screening patient-specific glioblastoma therapeutic agent or selecting safer and more effective patient-specific glioblastoma therapy.

Method for preparing patient-specific glioblastoma animal model, and uses thereof

One embodiment of the present invention provides a detection kit for detecting c-Met gene expression, wherein the detection kit includes a primer set which is specifically bound to the c-Met gene; and a cleavable probe which is specifically bound to the inside of a c-Met gene amplification product which is amplified by the primer set. Another embodiment of the present invention provides a method of measuring the c-Met gene expression by using the detection kit according to one embodiment of the present invention. The method according to one embodiment of the present invention is used to efficiently detect a low concentration of c-Met gene expression for cancer diagnosis and prognosis diagnosis.

Method for detecting a c-Met gene using cleavable probe

A screening method is described for selecting patient-specific anti-cancer agents reflecting individual genetic properties, in a precise and rapid manner, using an extremely small amount of cancer cells. Such screening method is useful for development of novel anti-cancer agents and the personalized medical field.

Method for screening patient-specific anti-cancer agent using limiting dilution assay

A cell analysis apparatus may include: an image processing unit imaging cultured cell colonies to convert the imaged cell colonies into digital signals; an outline extracting unit extracting outlines of the cell colonies from image data obtained from the image processing unit; a size calculating unit calculating sizes of the cell colonies from the extracted outlines; and a selecting unit comparing the sizes of the cell colonies with a preset value to select grown cell colonies.

Cell analysis apparatus and method

One embodiment of the present invention provides a detection kit for detecting a chronic myelogenous leukemia (CML) gene expression, wherein the detection kit includes a primer set which is specifically bound to the CML gene; and a cleavable probe which is specifically bound to the inside of a CML gene amplification product which is amplified by the primer set. Another embodiment of the present invention provides a method of measuring the CML gene expression by using the detection kit according to one embodiment of the present invention. The method according to one embodiment of the present invention is used to efficiently detect a low CML gene expression for CML diagnosis and prognosis diagnosis.

Method for multiplex-detecting chronic myelogenous leukemia gene using cleavable probe

The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate, either by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway, or by transfecting stem cells with the c-MET gene and treating the transfected stem cells with the HGF ligand protein to activate the c-MET/HGF signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway or the c-MET/HGF signaling pathway, stem cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.

Composition for proliferating stem cells by activating notch signaling

Method for proliferating stem cells by activating c-MET/HGF signaling and notch signaling

Growing community of inventors

Seoul, South Korea

Do Hyun Nam